-
公开(公告)号：US20230088694A1
公开(公告)日：2023-03-23
申请号：US17610291
申请日：2020-11-26
发明人： Eiji IDEUE , Masafumi KOMIYA , Shoukou LEE , Shunichiro UESUGI , Yuta FUNAKOSHI
IPC分类号： C07D413/14 , A61P25/26 , C07D487/08 , C07D401/12
摘要： The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin type 2 receptor, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.
-
公开(公告)号：US20220273563A1
公开(公告)日：2022-09-01
申请号：US17570635
申请日：2022-01-07
发明人： Akihisa Fukushima
摘要： The present invention provides a liposome useful as a vaccine adjuvant. More specifically, the present invention provides a liposome which comprises a lipid bilayer comprising dimyristoylphosphatidylcholine and egg phosphatidylglycerol and a conjugated compound in which a low-molecular weight compound enhancing the physiological activity of TLR7 is bound to squalene via a linker, said conjugated compound being encapsulated in the lipid bilayer.
-
公开(公告)号：US20220211844A1
公开(公告)日：2022-07-07
申请号：US17600919
申请日：2020-04-03
发明人： Hitoshi Ban , Yosuke Takanashi , Masashi Goto , Natsuko Suginobe , Yusuke Imazaki , Yoshiko Iwata
IPC分类号： A61K39/39 , A61K39/00 , A61P37/04 , A61P35/00 , C07D239/49
摘要： The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.
-
公开(公告)号：US20220193075A1
公开(公告)日：2022-06-23
申请号：US17606394
申请日：2020-04-24
发明人： Mitsumasa Kurita , Yuki Ikeda , Mitsuhiro Nakato
IPC分类号： A61K31/506 , A61K31/198 , A61P25/16 , A61K9/00 , A61K9/70 , A61K31/4015 , A61K31/496
摘要： The present invention provides a therapeutic drug that is useful for levodopa induced dyskinesia in Parkinson's disease. In particular, the present invention provides a composition and method for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, especially levodopa induced dyskinesia (PD-LID), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
-
公开(公告)号：US11352357B2
公开(公告)日：2022-06-07
申请号：US17526722
申请日：2021-11-15
发明人： Eiji Ideue , Masafumi Komiya , Shoukou Lee , Shunichiro Uesugi , Yuta Funakoshi
IPC分类号： C07D471/04 , C07D519/00 , C07D487/04
摘要： The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin type 2 receptor, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.
-
公开(公告)号：US20220144927A1
公开(公告)日：2022-05-12
申请号：US17430704
申请日：2020-10-16
发明人： Mitsuhiro MATONO , Jun SAKAI , Toru NAGAI , Naoki TANUMA , Richard BUICK
IPC分类号： C07K16/18 , A61P35/00 , G01N33/577 , G01N33/532
摘要： The present invention aims to provide a humanized antibody or an antigen-binding fragment thereof having stable physical property, superior in tumor accumulation, and capable of binding to mucin subtype 5AC.
The above-mentioned problem is solved by the present invention that provides a humanized antibody or an antigen-binding fragment thereof having a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 1-4 or a mutated amino acid sequence thereof, and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 5-8 or a mutated amino acid sequence thereof, and capable of binding to mucin subtype 5AC.-
公开(公告)号：US11273212B2
公开(公告)日：2022-03-15
申请号：US16348803
申请日：2017-11-10
IPC分类号： A61K39/015 , A61P33/06 , A61K39/05 , A61K39/13 , C07K14/445 , C07K16/20 , C12N15/10
摘要： The present invention relates to a polypeptide consisting of an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, (b) an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8 by substitution, deletion, addition, or insertion of 1 to 10, preferably 1-5, more preferably 1, 2 or 3 amino acids, and (c) an amino acid sequence that has at least 95%, preferably 97%, more preferably 99% sequence identity with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, and a malaria vaccine comprising the polypeptide, for example.
-
公开(公告)号：US11267797B2
公开(公告)日：2022-03-08
申请号：US16907463
申请日：2020-06-22
IPC分类号： C07D307/92 , C07H15/26 , A61P35/00 , C07D405/12 , C07D407/12 , C07F9/655 , C07H7/06
摘要： The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11214771B2
公开(公告)日：2022-01-04
申请号：US15521334
申请日：2015-10-23
IPC分类号： C12N5/0793 , C12N5/0797 , A61K35/30 , A61L27/00 , A61K35/12 , C12Q1/02 , C12N5/079 , A61L27/38 , G01N33/50
摘要： The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGFβ family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.
-
公开(公告)号：US20210386739A1
公开(公告)日：2021-12-16
申请号：US17461015
申请日：2021-08-30
发明人： Mitsumasa Kurita , Yuki Ikeda , Mitsuhiro Nakato
IPC分类号： A61K31/506 , A61K31/198 , A61P25/16 , A61K9/00 , A61K9/70 , A61K31/4015 , A61K31/496
摘要： The present invention provides a therapeutic drug that is useful for levodopa induced dyskinesia in Parkinson's disease. In particular, the present invention provides a composition and method for treating, improving, delaying the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, especially levodopa induced dyskinesia (PD-LID), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
-
-
-
-
-
-
-
-
-
搜索结果
268 条记录 (耗时 0.028 秒)
